Gilead to acquire Tubulis for up to $5 billion to strengthen its oncology portfolio

The acquisition complements Gilead’s existing oncology expertise and development infrastructure

India’s Dapagliflozin Moment: Why USFDA’s generic greenlight wave matters

In just the last few days, companies including Lupin, Biocon, Alembic Pharmaceuticals and Aurobindo Pharma have announced approvals for 5 mg and 10 mg tablets, all bioequivalent to Farxiga

RoosterBio taps MineBio to supercharge hMSC & exosome solutions in China

Insmed’s Brensocatib fails to hit endpoints in hidradenitis suppurativa study

The results were consistent across both the 10 mg and 40 mg treatment arms

Apnimed secures $150 million financing to fuel US launch of oral sleep apnea drug AD109

The financing includes a four-year interest-only period, extendable to five years if a net sales milestone is achieved

Amgen’s TEPEZZA injection clears Phase 3 trial with high efficacy

The trial also demonstrated significant improvements across multiple secondary endpoints

IndiaAI, CDSCO launch hackathon to accelerate health innovation approvals

AI challenge offers Rs 10 lakh top prize and potential ?50 lakh deployment contract; applications open till April 17

Regeneron and TriNetX forge $200M partnership to supercharge drug discovery and digital health

TriNetX will provide Regeneron secure, licensed access to de-identified health data from its global network of health system partners

WHO updates global guidelines to combat opioid crisis

Opioid dependence remains a major driver of death and disease worldwide

OneCyte and Kemp Proteins to revolutionize cell line development

Biopharma companies face persistent hurdles in cell line development, including long timelines, low yields, and high failure rates for novel molecules